Scientific R&D

sbk002 is a Class 1 innovative drug for the secondary prevention of atherosclerotic thrombotic events, such as in patients with myocardial infarction, ischemic stroke, or peripheral arterial disease. It demonstrates enhanced safety, reduced hepatic and renal burden, and minimized drug-drug interactions.

China: Accepted by the CDE in December 2025.
United States: sbk002 received FDA IND approval on February 1, 2025.
European Union: Plans to submit an MAA application to the EMA in 2026.

SBK001 is a Class 1 innovative drug with a novel compound structure for the treatment of acute lung injury (ALI) and expectoration. It improves clinical treatment safety, achieves better efficacy, and provides more treatment options for patients with respiratory diseases.

China: Phase II clinical trials have completed enrollment.
United States/European Union: Registration evaluation is currently underway.

SBK007 is a Class 1 innovative drug with a novel compound structure, targeting two indications: treatment of acute urticaria in adults and relief of symptoms related to allergic rhinitis (seasonal and perennial). It is a new, highly effective third-generation antihistamine anti-allergy drug.

China: Phase I clinical trials for acute urticaria in adults have been completed, and Phase II clinical trials for seasonal allergic rhinitis have been initiated.
United States: Plans to submit an IND application to the FDA in 2026.

SBK009 can effectively inhibit ADP-induced platelet aggregation with favorable safety and tolerability, making it a promising new option for antiplatelet therapy.

China: SBK009 for injection has received clinical trial approval (IND) from the National Medical Products Administration (NMPA) for antiplatelet therapy during the perioperative period of PCI.
United States: Plans to submit an IND application to the FDA in 2026.

SBK013 is a Class 1 innovative drug with a novel compound structure, intended for the prevention of arterial and venous thromboembolic diseases. It aims to compete with existing anticoagulants by addressing the shortcomings of current treatment options and providing a more effective solution for the prevention and treatment of thrombotic diseases.

China: SBK013 received clinical trial approval (IND) from the National Medical Products Administration (NMPA) on March 6, 2025, with plans to submit an IND application for new indications in 2026.
United States: Plans to submit an IND application to the FDA in 2026.

SBK008 is a Class 1 innovative drug with a novel compound structure. It effectively improves neurological deficits while significantly ameliorating cognitive dysfunction, making it a promising new option for the treatment of acute ischemic stroke.

SBK011 is a diagnostic reagent specifically designed for the OGTT test. Its launch will successfully fill the gap in commercially available reagents in this field in China, providing a new solution for diabetes screening and diagnosis, and significantly enhancing the standardization and convenience of diabetes diagnosis and treatment.

Shibeikang plans to submit a New Drug Application (NDA) in 2026.

SBK010 is a Class 2 innovative drug with an improved formulation for the treatment of ischemic stroke. It demonstrates excellent therapeutic efficacy while significantly improving patient compliance.

SBK012 is a Class 2 innovative drug with an improved formulation for the treatment of acute ischemic stroke. It has successfully overcome the limitations of existing medications, completed clinical trials with favorable data across all evaluation metrics.

Shibeikang plans to submit a New Drug Application (NDA) in 2026.

SBK014 is an improved formulation designed to enhance medication compliance in pediatric patients or adult patients with dysphagia. It improves ease of swallowing, enhances taste, provides more precise dosing for pediatric patients requiring weight-based administration, and offers greater convenience.

SBK017 is a Chemical Class 2 new drug, an improved formulation designed for patients with dysphagia.

SHLQ Syrup is an approved Class 2 chemical new drug (GYZZ H20240034) indicated for sedation and hypnosis in children prior to surgical examinations or procedures. As China's first commercially available pediatric-specific SHLQ Syrup formulation, it significantly improves medication safety and compliance in children.

SHLQ Syrup included in NRDL on Nov 28, 2024